


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A compound according to the general Formula (I)



the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the *N*-oxide form thereof, wherein :

X is CH₂, N-R⁷, S or O ;

R⁷ is selected from the group consisting of hydrogen, alkyl, Ar, Ar-alkyl, alkylcarbonyl, alkyloxycarbonyl and mono- and di(alkyl)aminocarbonyl ;


R¹, R², R¹⁴, R¹⁵ are each, independently from each other, selected from the group consisting of

- hydrogen ;
- halo ;
- a radical selected from the group consisting of hydroxy, -OSO₂H, -OSO₂CH₃, alkyloxy, alkyloxyalkyloxy, alkyloxyalkyloxyalkyloxy, tetrahydrofuranyloxy, alkylcarbonyloxy, alkyloxyalkylcarbonyloxy, pyridinylcarbonyloxy, alkylcarbonyloxyalkyloxy, alkyloxyalkylcarbonyloxyalkyloxy, alkyloxyalkylcarbonyloxy, alkenyloxy, alkenylcarbonyloxy, mono- or di(alkyl)aminoalkyloxy, mono- or di(alkyl)aminocarbonyloxyalkyloxy ;
- a radical selected from the group consisting of cyano, CN-OH, CN-oxyalkyl, alkyl, alkyloxyalkyl, alkyloxyalkyloxyalkyl, alkyloxyalkyloxyalkyloxyalkyl,

alkylcarbonylalkyl, alkylcarbonyloxyalkyl, alkyloxycarbonylalkyl, Ar-alkyl, Ar-carbonylalkyl, Ar-oxyalkyl, mono- or di(alkyl)aminoalkyl, mono- or di(alkylcarbonyl)aminoalkyl, mono- or di(alkyl)aminocarbonylalkyl, Het-alkyl, formyl, alkylcarbonyl, alkyloxycarbonyl, alkyloxyalkylcarbonyl, mono- or di(alkyl)aminocarbonyl, Ar-carbonyl and Ar-oxycarbonyl ;

$-N-R^{10}R^{11}$ wherein R^{10} and R^{11} each, independently from each other, are selected from the group consisting of hydrogen, alkyl, Ar, pyridinyl, Ar-alkyl, pyrrolidinylalkyl, piperidinylalkyl, homopiperidinylalkyl, piperazinylalkyl, morpholinylalkyl, mono- or di(alkyl)aminoalkyl, alkylcarbonyl, alkenylcarbonyl, Ar-carbonyl, pyridinylcarbonyl, alkyloxycarbonyl, mono- or di(alkyl)aminocarbonyl, mono- or di(Ar)aminocarbonyl, mono- or di(alkyloxycarbonylalkyl)aminocarbonyl, pyrrolidinylcarbonyl, aminoiminomethyl, alkylaminoiminomethyl, *N*-benzylpiperazinyliminomethyl, alkylsulphonyl and Ar-sulphonyl ; or


R^{10} and R^{11} may be taken together and with the N may form a monovalent radical selected from the group consisting of



wherein :

R^{12} is selected from the group consisting of hydrogen, alkyl, Ar, Ar-alkyl, Ar-alkenyl, alkylcarbonyl, alkyloxycarbonyl, alkyloxyalkylcarbonyl and mono- or di(alkyl)aminocarbonyl ;

- each R^{13} is, independently from each other, selected from the group consisting of alkyl, oxo, Ar, Ar-alkyl, Ar-alkenyl and alkyloxycarbonyl ;
- q is an integer ranging from 0 to 6 ;
- alkylthio ;
 - Ar and Het ;
- ~~with the proviso~~ with the proviso that at least one of R^{14} and R^{15} is not hydrogen.
- Ar is phenyl or naphthyl, optionally substituted with one or more halo, cyano, oxo, hydroxy, alkyl, formyl, alkyloxy or amino radicals ;
- Het is a heterocyclic radical selected from the group consisting of Het¹, Het² and Het³ ;
- Het¹ is an aliphatic monocyclic heterocyclic radical selected from the group of pyrrolidinyl, dioxolyl, imidazolidinyl, pyrrazolidinyl, piperidinyl, dioxyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl and tetrahydrofuryl ;
- Het² is a semi-aromatic monocyclic heterocyclic radical selected from the group consisting of 2H-pyrrolyl, pyrrolinyl, imidazolinyl and pyrrazolinyl ;
- Het³ is an aromatic monocyclic heterocyclic radical selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl and triazinyl; or an aromatic bicyclic heterocyclic radical selected from the group of quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and benzothienyl ;
- wherein each Het-radical may optionally be substituted on either a carbon or heteroatom with halo, hydroxy, alkyloxy, alkyl, Ar, Ar-alkyl, formyl, alkylcarbonyl or pyridinyl ;
- a and b are asymmetric centers ;
- (CH₂)_m is a straight hydrocarbon chain of m carbon atoms, m being an integer ranging from 1 to 4 ;
- Pir is a radical according to any one of Formula (IIa), (IIb) or (IIc)



optionally substituted with n radicals R^8 , wherein :

each R^8 is independently from each other, selected from the group consisting of hydroxy, amino, nitro, cyano, halo and alkyl ;

n is an integer ranging from 0 to 5 ;


R^9 is selected from the group consisting of hydrogen, alkyl and formyl ;

R^3 represents an optionally substituted aromatic homocyclic or heterocyclic ring system together with an optionally substituted and partially or completely hydrogenated hydrocarbon chain of 1 to 6 atoms long with which said ring system is attached to the Pir radical and of which may contain one or more heteroatoms selected from the group of O, N and S ;

alkyl represents a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms, optionally substituted with one or more halo, cyano, oxo, hydroxy, formyl or amino radicals and

alkenyl represents a straight or branched unsaturated hydrocarbon radical having one or more double bonds, optionally substituted with one or more halo, cyano, oxo, hydroxy, formyl or amino radicals.

2. (Currently Amended) A compound according to claim 1, wherein characterized in ~~that~~ R^3 is a radical according to any one of Formula (IIIa), (IIIb) or (IIIc)



wherein :

- d is a single bond while Z is a bivalent radical selected from the group consisting of $-\text{CH}_2-$, $-\text{C}(=\text{O})-$, $-\text{CH}(\text{OH})-$, $-\text{C}(=\text{N}-\text{OH})-$, $-\text{CH}(\text{alkyl})-$, $-\text{O}-$, $-\text{S}-$, $-\text{S}(=\text{O})-$, $-\text{NH}-$ and $-\text{SH}-$; or d is a double bond while Z is a trivalent radical of formula $=\text{CH}-$ or $=\text{C}(\text{alkyl})-$;
- A is a 5- or 6-membered aromatic homocyclic or heterocyclic ring, selected from the group consisting of phenyl, pyranyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, oxadiazolyl and isoxazolyl ;
- p is an integer ranging from 0 to 6 ;
- R^4 and R^5 are each, independently from each other, selected from the group consisting of hydrogen, alkyl, Ar, biphenyl, halo and cyano ; or
- R^4 and R^5 may be taken together to form a bivalent radical $-\text{R}^4-\text{R}^5-$ selected from the group of $-\text{CH}_2-$, $=\text{CH}-$, $-\text{CH}_2-\text{CH}_2-$, $-\text{CH}=\text{CH}-$, $-\text{O}-$, $-\text{NH}-$, $=\text{N}-$, $-\text{S}-$, $-\text{CH}_2\text{N}(\text{alkyl})-$, $-\text{N}(\text{alkyl})\text{CH}_2-$, $-\text{CH}_2\text{NH}-$, $-\text{NHCH}_2-$, $-\text{CH}=\text{N}-$, $-\text{N}=\text{CH}-$, $-\text{CH}_2\text{O}-$ and $-\text{OCH}_2-$;
- each R^6 is independently from each other, selected from the group consisting of hydroxy, amino, nitro, cyano, halo, carboxyl, alkyl, Ar, alkyloxy, Ar-oxy, alkylcarbonyloxy, alkyloxycarbonyl, alkylthio, mono- and di(alkyl)amino, alkylcarbonylamino, mono- and di(alkyl)aminocarbonyl, mono- and di(alkyl)aminocarbonyloxy, mono- and di(alkyl)aminoalkyloxy ; or two vicinal radicals R^6 may be taken together to form a bivalent radical $-\text{R}^6-\text{R}^6-$ selected

from the group consisting of -CH₂-CH₂-O-, -O-CH₂-CH₂-, -O-CH₂-C(=O)-, -C(=O)-CH₂-O-, -O-CH₂-O-, -CH₂-O-CH₂-, -O-CH₂-CH₂-O-, -CH=CH-CH=CH-, -CH=CH-CH=N-, -CH=CH-N=CH-, -CH=N-CH=CH-, -N=CH-CH=CH-, -CH₂-CH₂-CH₂-, -CH₂-CH₂-C(=O)-, -C(=O)-CH₂-CH₂-, -CH₂-C(=O)-CH₂- and -CH₂-CH₂-CH₂-CH₂- and R¹⁶ is selected from the group consisting of hydrogen, alkyl, Ar and Ar-alkyl.

3. (Currently Amended) A compound according to claim 2, wherein ~~characterized in that~~ X = O ; m = 1 ; Pir is a radical according to Formula (IIa) wherein n = 0 ; R³ is a radical according to Formula (IIIb) wherein d is a double bond while Z is a trivalent radical of formula =CH-, A is a phenyl ring, R⁴ is hydrogen or alkyl and R⁵ and R¹⁶ are each hydrogen.

4. (Currently Amended) A compound according to claim 1, wherein, ~~any one of claims 1-3, characterized in that~~ R¹, R², R¹⁴ and R¹⁵ are each, independently from each other, selected from the group consisting of hydrogen ; halo ; cyano ; hydroxy ; alkyloxy ; alkylcarbonyloxyalkyloxy ; alkyloxyalkylcarbonyloxyalkyloxy ; monoalkylaminocarbonyloxyalkyloxy ; morpholinylalkyl ; -NR¹⁰R¹¹, wherein R¹⁰ and R¹¹ each, independently from each other, are selected from the group of hydrogen, pyrrolidinylalkyl, mono- or di(alkyl)aminoalkyl, pyridinyl, alkylcarbonyl and phenylalkyl ; or R¹⁰ and R¹¹ are taken together to form a radical (a) wherein R¹³ is oxo or a radical (f) wherein R¹² is hydrogen and q = 0 ; ~~with the proviso~~ with the proviso that at least one of R¹⁴ and R¹⁵ is not hydrogen.

5. (Currently Amended) A compound according to claim 1, wherein ~~any one of claims 1-3, characterized in that~~ R¹ and R² are both either hydrogen or methoxy and R¹⁴ and R¹⁵ are each, independently from each other, selected from the group consisting of hydrogen ; halo ; cyano ; hydroxy ; alkyloxy ; alkylcarbonyloxyalkyloxy ; alkyloxyalkylcarbonyloxyalkyloxy ; monoalkylaminocarbonyloxyalkyloxy ; morpholinylalkyl ; -NR¹⁰R¹¹, wherein R¹⁰ and R¹¹ each, independently from each other, are selected from the group of hydrogen, pyrrolidinylalkyl, mono- or di(alkyl)aminoalkyl, pyridinyl, alkylcarbonyl and phenylalkyl ; or R¹⁰ and R¹¹ are taken together to form a radical (a) wherein R¹³ is oxo or a radical (f) wherein R¹² is hydrogen

and $q = 0$; ~~with the proviso~~ with the proviso that at least one of R^{14} and R^{15} is not hydrogen.

6. (Currently Amended) A compound which is degraded *in vivo* to yield a compound according to claim 1. ~~any one of claims 1-5.~~

7. (Currently Amended) A compound according to claim 1 ~~any one of claims 1-6~~ for use as a medicine.

8. (Currently Amended) The use of a compound according to claim 1 ~~any one of claims 1-6~~ for the manufacture of a medicament for treating depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders.

9. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient a therapeutically effective amount of a compound according to claim 1 ~~any one of claims 1-6.~~

10. (Currently Amended) A process for making a pharmaceutical composition ~~according to claim 9~~, comprising mixing a compound according to claim 1 ~~any one of claims 1-6~~ and a pharmaceutically acceptable carrier.

11. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient a therapeutically effective amount of a compound according to claim 1 ~~any one of claims 1-6~~ and one or more other compounds selected from the group consisting of antidepressants, anxiolytics, anti-psychotics and anti-Parkinson's disease drugs.

12. (Canceled)

13. (Currently Amended) The use of a compound according to claim 1 ~~any one of claims 1-6~~ for the manufacture of a medicament for the treatment and/or prophylaxis of depression,

anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders, said treatment comprising the simultaneous or sequential administration of a compound according to claim 1 ~~any one of claims 1-6~~ and one or more other compounds selected from the group consisting of antidepressants, anxiolytics, antipsychotics and anti-Parkinson's drugs.

14. (Currently Amended) A process for making a pharmaceutical composition ~~according to claim 11~~, comprising mixing a compound according to claim 1 ~~any one of claims 1-6~~ and a compound selected from the group consisting of antidepressants, anxiolytics, antipsychotics and anti-Parkinson's disease drugs and a pharmaceutically acceptable carrier.